Michael Quigley

Mike joined SV as a Venture Partner in 2021 and is the CEO of Therini Bio as well as on the Scientific Advisory Board of Enara Bio, both SV portfolio companies.

Prior to joining SV, Mike was Senior Vice President of Research Biology at Gilead Sciences, overseeing the company’s biology teams and preclinical programs as well as protein biotherapeutics and computational biology and bioinformatics efforts across all therapeutic areas. Prior to that, he was Vice President and Head, Tumor Microenvironment Modulation Thematic Research Center at Bristol-Myers Squibb and site head of the company’s Redwood City, California location. Earlier in his career Mike lead teams in Oncology Discovery at MedImmune and Janssen.

In his spare time you can find Mike with his wife and two daughters enjoying the outdoors and cycling around the Bay Area.

Academic credentials

BS, Marine Biology, Eckerd College; PhD, Immunology, Duke University; Postdoctoral Fellowship, Dana-Farber Cancer Institute, Department of Pediatric Oncology.